News & media

Dublin, Ireland – September 2, 2024: Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a study in “The Lancet”. This study, titled “Polyp detection with colonoscopy assisted by […]

Dublin, Ireland – 31 July 2024: Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) focused on pioneering medical devices powered by Artificial Intelligence, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the next generation GI Genius™ hardware, the latest […]

Dublin, Ireland – 24 July 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its 2024 half year results.   Key highlights Health Tech: Upfront payment of $100 million received from Medtronic related to expansion of AI-driven partnership; Cosmo expects to receive an additional $100m from Medtronic this year linked to new services and […]

Dublin, Ireland – 9 July 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2024 results on Wednesday, 24 July 2024 at 07:00 am CEST.   Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast presentation at 2:00 pm CEST to discuss […]

Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of 90% versus last year   Shareholders approved all other proposals of the Board of Directors, including the adoption of the FY2023 annual accounts and updates to the remuneration policy of the Company   Dublin, Ireland – 5 July 2024: Cosmo […]

Dublin, Ireland – 18 June 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reported that its partner and exclusive licensee of Lumeblue® (Methylene Blue MMX®) for China, China Medical System Holdings Limited (“CMS”) (SEHK: 867), has received the approval for the innovative product in the territory by the National Medical Products Administration of China […]

Dublin, Ireland – 3 June 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) with its Cosmo Intelligent Medical Devices division (“Cosmo IMD”) is consolidating its strategy to accelerate the adoption of responsible and regulated AI in healthcare, obtaining pragmatic results in its mission to address unmet clinical needs and improve patient outcomes.   GI […]

Dublin, Ireland – 31 May 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its final audited results for the financial year 2023.   Financial highlights   As previously announced when publishing preliminary unaudited 2023 figures on 20 March 2024, Cosmo delivered strong growth across its core business in 2023. The core business […]

Dublin, Ireland – 24 May 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today’s annual general meeting of shareholders.   A total of 7,417,916 ordinary shares in the share capital of Cosmo were represented at this annual general meeting of shareholders constituting 42.28% of […]

  Dublin, Ireland – 29 April 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that the company has been granted extension until 31 May 2024 to publish its 2023 annual report and to file such report with SIX Exchange Regulation AG.   Paragraph I. of the decision of SIX Exchange Regulation AG which […]